Elizabeth Walsh, PMP, ACRP-CP, is a clinical development executive specializing in execution strategy and delivery across complex development programs. With more than 25 years of experience spanning sponsor organizations, CROs, and research environments, she has led global Phase I-IV programs from early development through regulatory submission and commercialization.Her work focuses on integrating clinical execution into development strategy, ensuring operational assumptions are tested early and sponsor oversight remains active across outsourced models. She has built and led Clinical Operations organizations, supported IND, NDA, and BLA submissions, and guided programs across oncology, rare disease, neurology, immunology, and infectious disease.She is the founder of Walsh Clinical Advisory, where she advises biotech sponsors on clinical execution and oversight.
In this Q&A, Elizabeth Walsh, PMP, ACRP-CP, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint, discusses the persistent misconceptions about sponsor accountability, why execution gaps originate long before study startup, and what genuine inspection readiness looks like when it is built in from the outset.
Clinical development operates as an integrated system where dependencies persist across phases and vendors, but treating contracts as execution handoffs creates invisible oversight gaps that surface later as vendor performance problems, timeline slips, or inspection findings.
In this video interview, Elizabeth Walsh, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint, describes what it means to accumulate inspection readiness rather than assemble it—and why the story regulators reconstruct is determined long before an inspection is announced.
In this video interview, Elizabeth Walsh, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint, explains why execution failures surface where they're visible but originate where conditions were set—and why clinical operations leaders too often inherit problems they had no hand in creating.
In this video interview, Elizabeth Walsh, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint, identifies where the most consequential capability gaps accumulate—from protocol-to-execution bridging to how sponsor oversight roles are structured and staffed.
In this video interview, Elizabeth Walsh, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint, makes the case that the assumptions accumulated at the moment of a product development decision govern everything that follows—and why deferring that work doesn't save time, it just makes it more expensive to fix.
In this video interview, Elizabeth Walsh, founder of Walsh Clinical Advisory and co-author of The Clinical Execution Blueprint, explains why the belief that outsourcing execution transfers accountability is the most consequential and least examined gap in how sponsor organizations are structured.
Protocol assumptions about patients, visit schedules, timelines, and vendors are rarely tested against operational reality until startup, but early engagement of experienced execution strategists can identify and mitigate feasibility gaps before commitments harden into expensive course corrections.
Execution instability often originates in strategy timing rather than study conduct, which sponsors can correct by integrating execution oversight expertise earlier in development decisions.
